Map the technology landscape, key players, and patent strategy in a therapeutic area
PubMed-grounded biomedical AI that maps a drug-delivery technology or therapeutic platform end to end — the underlying science, the companies and patent families, and the gap between mechanistic claims and clinical reality. Built for pharma R&D strategists, business-development and licensing teams, and investment due-diligence analysts.
Try this workflow live
Pre-loaded BioSkepsis session mapping the oral peptide delivery landscape — mechanisms, players and patents, claims versus clinical reality, and benchmarked formulation strategies.
See it in the app → Start freeBuilt for pharma R&D strategy, licensing, and due diligence
- Pharma R&D strategists: map a modality's science, key players, and white space before committing program resources.
- Business-development & licensing teams: pressure-test a target platform's patent landscape and translational evidence ahead of a deal.
- Investment & due-diligence analysts: separate marketed promise from peer-reviewed reality before a term sheet.
The 6-step workflow — technology landscape to evidence-ranked strategies
Start broad with the science and the commercial landscape, then map the competitive and patent picture, and finish with the questions that separate hype from translational evidence: do the claims hold up in humans, what limitations recur, and which approaches have the strongest clinical evidence.
Enter a technology-focused research question covering mechanisms, formulations, and the commercial landscape
Frame the question around a specific drug-delivery technology, therapeutic modality, or platform science. Ask about mechanisms of action, recent patents or formulation strategies, and the key players involved.
Review the initial AI synthesis as a technology landscape overview
BioSkepsis returns a structured answer covering the underlying science (e.g., how each absorption enhancer works at the molecular level), the marketed technologies (e.g., Rybelsus/SNAC, Mycapssa/C8, GIPET/C10), and the emerging approaches (e.g., nanocarriers, robotic pills). Check the unverified citations panel for flagged references before you rely on any single number.
Map the competitive landscape: companies, platforms, and patent families
Ask which companies and patent families dominate the space, and what citation clusters reveal about where innovation is converging. This produces a structured overview of key players, their proprietary platforms, and the emerging innovation hubs.
Assess the gap between mechanistic claims and clinical reality
Ask how well the mechanistic claims in patents and preclinical studies hold up when tested in actual human pharmacokinetic studies. This is the critical "does it actually work?" question that separates hype from translational evidence.
Identify recurring technical limitations and unresolved challenges
Ask what limitations are repeatedly disclosed across patents, publications, and clinical reports. This surfaces the systemic barriers the field has not yet solved — the problems that any new entrant or investor must account for.
Benchmark formulation approaches by clinical evidence strength
Ask which specific formulation strategies have the strongest clinical evidence for meaningful improvements — not just in bioavailability numbers, but in patient-relevant outcomes compared to existing therapies.
What you walk away with
Technology landscape overview
The underlying science, the marketed technologies, and the emerging approaches — with unverified citations flagged.
Competitive & patent map
Key players, proprietary platforms, recurring patent families, and the citation clusters that mark innovation hubs.
Claims-versus-reality assessment
Where patent and preclinical mechanistic claims hold up against human pharmacokinetic and clinical data.
Evidence-ranked strategies
Formulation approaches benchmarked by clinical-evidence strength and patient-relevant outcomes, not just bioavailability numbers.
Walk through the live workflow
Pre-loaded BioSkepsis session demonstrating the full competitive-intelligence workflow with verified citations at every step.
See it in the app →Honest limits — what AI will not do for competitive intelligence
- AI maps the published and patent literature — not confidential pipelines. BioSkepsis cannot reveal unpublished filings, internal R&D, or undisclosed deal terms.
- Patent-family analysis is directional, not a freedom-to-operate opinion. Use it to scope the landscape and brief counsel — get a formal FTO/patent search for licensing and clearance decisions.
- Citation flags surface likely errors, not certainty. Verify each PMID and effect size against the source before it enters a due-diligence memo.
- Final strategic judgement is human. BioSkepsis builds the evidence base; your team weighs commercial, regulatory, and IP risk.
Frequently asked questions
What therapeutic areas and technologies does this competitive-intelligence workflow support?
Any drug-delivery technology, therapeutic modality, or platform science with a published and patent footprint — oral peptide delivery, mRNA/LNP platforms, antibody-drug conjugates, cell and gene therapy, small-molecule formulation science, and more. BioSkepsis draws on a 40M+ paper biomedical corpus including PubMed, bioRxiv, and medRxiv, alongside the patent and formulation literature these papers cite.
Can BioSkepsis analyse patent families directly?
BioSkepsis surfaces the companies, platforms, and patent families that recur across the published and patent literature, and reveals citation clusters that point to emerging innovation hubs. This is directional landscape intelligence — it is not a freedom-to-operate (FTO) opinion. Use it to scope the field and brief counsel, not to replace a formal patent search.
How does it separate marketing hype from real clinical evidence?
Steps 4 through 6 are built for exactly this. You ask how well mechanistic claims in patents and preclinical work hold up in human pharmacokinetic and clinical studies, which limitations recur across the field, and which formulation strategies have the strongest clinical evidence for patient-relevant outcomes — not just bioavailability numbers. BioSkepsis grounds each answer in verified PMIDs and flags unverified citations.
Is the output suitable for an investment due-diligence memo?
The output maps cleanly into the evidence sections of a due-diligence memo or licensing assessment: technology overview, competitive map, claims-versus-reality, and benchmarked approaches with verified citations. Final investment or deal decisions require your own commercial, regulatory, and legal review — BioSkepsis builds the literature foundation your analysts and counsel work from.
Does it cover preprints and clinical-trial literature, not just journals?
Yes. The corpus spans peer-reviewed journals, preprints (bioRxiv, medRxiv), pharmacology and pharmacokinetics, and clinical-trial reports — so the landscape reflects both the established record and emerging activity that has not yet reached final publication.
Map your next technology landscape
PubMed-grounded biomedical AI. Verified citations. Science, players, and patents to clinical reality in one workflow. Free tier — no credit card.
See it in the app Start free